158.69
-0.44 (-0.28%)
Penutupan Terdahulu | 159.13 |
Buka | 156.06 |
Jumlah Dagangan | 340,405 |
Purata Dagangan (3B) | 2,334,142 |
Modal Pasaran | 27,453,370,368 |
Harga / Pendapatan (P/E TTM) | 21.62 |
Harga / Pendapatan (P/E Ke hadapan) | 13.42 |
Harga / Jualan (P/S) | 1.87 |
Harga / Buku (P/B) | 4.61 |
Julat 52 Minggu | |
Tarikh Pendapatan | 21 Jul 2025 - 25 Jul 2025 |
Margin Keuntungan | 8.61% |
Margin Operasi (TTM) | 13.71% |
EPS Cair (TTM) | 7.34 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 2.50% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | -13.50% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 242.91% |
Nisbah Semasa (MRQ) | 0.820 |
Aliran Tunai Operasi (OCF TTM) | 2.76 B |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.16 B |
Pulangan Atas Aset (ROA TTM) | 5.30% |
Pulangan Atas Ekuiti (ROE TTM) | 21.64% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Diagnostics & Research (US) | Menurun | Menurun |
Diagnostics & Research (Global) | Menurun | Menurun | |
Stok | IQVIA Holdings, Inc. | Menurun | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 1.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 3.5 |
Purata Bergerak Teknikal | -1.0 |
Osilator Teknikal | 2.0 |
Purata | 1.38 |
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. |
|
Sektor | Healthcare |
Industri | Diagnostics & Research |
Gaya Pelaburan | Mid Core |
% Dimiliki oleh Orang Dalam | 0.96% |
% Dimiliki oleh Institusi | 95.68% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Farallon Capital Management Llc | 31 Mar 2025 | 3,411,851 |
Longview Partners (Guernsey) Ltd | 31 Mar 2025 | 2,028,276 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 216.00 (Truist Securities, 36.11%) | Beli |
Median | 177.00 (11.54%) | |
Rendah | 160.00 (HSBC, 0.83%) | Pegang |
Purata | 179.14 (12.89%) | |
Jumlah | 4 Beli, 3 Pegang | |
Harga Purata @ Panggilan | 148.20 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
JP Morgan | 19 May 2025 | 177.00 (11.54%) | Beli | 143.54 |
Mizuho | 15 May 2025 | 190.00 (19.73%) | Beli | 140.43 |
09 Apr 2025 | 210.00 (32.33%) | Beli | 157.02 | |
Baird | 07 May 2025 | 161.00 (1.46%) | Pegang | 153.30 |
Barclays | 07 May 2025 | 165.00 (3.98%) | Pegang | 153.30 |
10 Apr 2025 | 170.00 (7.13%) | Pegang | 143.22 | |
UBS | 07 May 2025 | 185.00 (16.58%) | Beli | 153.30 |
HSBC | 25 Apr 2025 | 160.00 (0.83%) | Pegang | 150.28 |
Truist Securities | 10 Apr 2025 | 216.00 (36.11%) | Beli | 143.22 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |